Heart failure is a public health concern that is linked to higher rates of hospitalization, mortality, and healthcare resource utilization. The incidence of heart failure in Europe is approximately five per 1,000 person-years in adults, with a prevalence of heart failure estimated to be between 1% and 2% of the population. Despite advances in pharmacological and device-based heart failure therapies, the prognosis of heart failure is still worse than that of many cancer types, with a 5-year mortality rate varying from 45% to 60% in adults. A comprehensive understanding of the sociodemographic, clinical, and biological characteristics of patients with heart failure is essential for developing novel strategies to improve outcomes.
 

Identifying barriers to guideline-directed medical therapy implementation in a real-world setting is critical for decreasing the risk of heart failure hospitalization and mortality. A comprehensive and well-designed heart failure registry can determine the clinical characteristics of patients with heart failure, identify patient-, physician-, and healthcare system-related factors for the non-use of evidence-based therapies, and improve the implementation of guideline-directed medical therapy.
 

The primary objective of the Türkiye Heart Failure (TURK-HF) Registry is to provide a comprehensive description of the epidemiology, sociodemographic and clinical characteristics, and quality of life of individuals with heart failure, irrespective of ejection fraction, who are either inpatients or outpatients. The TURK-HF Registry also seeks to delineate diagnostic and therapeutic strategies and ascertain participants' long-term prognosis.